



Utilization of Immunoglobulin Y (IgY) as Alternatives to Laboratory Animals in Human and Veterinary Medical Practice: A Review

Viswanathan Naveenkumar^{1#}, B.S. Pradeep Nag^{2#}, Kannan Porteen³, Arasan Varun⁴, R. Uma Rani¹, S. Sasikumar¹, D. Balasubramanyam⁵

10.18805/ag.R-2479

ABSTRACT

Emerging infectious diseases and antibiotic resistance impose major threats to animals and humans throughout the world. The Emergence of various infectious and pandemic diseases alarms the need for prophylactic and therapeutic regimens in protecting both animals and humans. Hence, researchers are trying to identify newer methodologies to overcome the existing issues for better immune response and antibiotic resistance. In this view, chicken immunoglobulin Y (IgY) has gained momentum due to its role in prophylactic, therapeutic and diagnostic modalities with varying success rate. In an unpredictable and contagious COVID-19 like situations, the role of passive immunization through chicken immunoglobulin has turned to be important for controlling infectious disease transmission. This review focus on the immunoprophylactic and immunotherapeutic role of IgY in human and animal diseases and to explore the use of IgY for veterinary and human medicine.

Key words: Chicken immunoglobulin Y, Human, Immunology, Passive, Prophylaxis, Review, Therapeutic, Veterinary practice.

In recent times, emerging, reemerging infectious diseases and antimicrobial drug resistance are the predominant reasons for the failure of treating diseases in individuals. The antimicrobial resistance is one of the potent threats for maintaining global health in the current decade (Asokan and Kasimanickam 2013; Ventola, 2015). Over 100 years of clinical practice, antibiotics are one of the major drugs used in human and animal medical practice with various modes of utility such as prophylactic, therapeutic and growth promoters (Turner *et al.*, 2001; Cromwell, 2002; Diraviyam *et al.*, 2014). Indiscriminate and injudicious use of antibiotics have resulted in antibiotic resistance among common pathogens with the potential to affect humans and animals. In such circumstances, researchers are currently working on drugs or molecules which are “alternative to antibiotics”, with varying success rate (Asokan and Kasimanickam 2013; Diraviyam *et al.*, 2014). Avian immunoglobulin Y (IgY) has recently gained importance in the medical practice with wide applicability such as immunoprophylaxis, immunotherapeutic and immunodiagnosics (Abbas *et al.*, 2019; Pereira *et al.*, 2019). In mammals, passive immunization of young ones is achieved through the colostrum. Similarly, IgY is the predominant immunoglobulin transferred to chick through egg yolk along with minor portion of IgA and IgM. Presently, IgY are developed against specific target antigen or gene with the various mode of utility. Additionally, non allergic with host immune system and less animal necessity for producing IgY based applications, accelerate the role of IgY in immunological platforms. Based on this fact this review addresses the role of avian immunoglobulin Y (IgY) as immunoprophylaxis and immunotherapeutic for human and animals, through a published literature survey.

¹Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University, Theni-625 602, Tamil Nadu, India.

²Southern Regional Station of National Dairy Research Institute, Bengaluru-560 030, Karnataka, India.

³Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai-600 051, Tamil Nadu, India.

⁴Krishi Vigyan Kendra, Villupuram-II, Tamil Nadu Veterinary and Animal Sciences University, Chinnasalem- 606 201, Tamil Nadu, India.

⁵Post Graduate Research Institute in Animal Sciences, Tamil Nadu Veterinary and Animal Sciences University, Kancheepuram-603 203, Tamil Nadu, India.

[#]These authors contributed equally to this work.

Corresponding Author: Kannan Porteen, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai-600 051, Tamil Nadu, India.

Email: rajavet2002@gmail.com

How to cite this article: Naveenkumar, V., Pradeep Nag, B.S., Porteen, K., Varun, A., Uma Rani, R., Sasikumar, S. and Balasubramanyam, D. (2022). Utilization of Immunoglobulin Y (IgY) as Alternatives to Laboratory Animals in Human and Veterinary Medical Practice: Review Article. *Agricultural Reviews*. DOI: 10.18805/ag.R-2479.

Submitted: 14-01-2022 **Accepted:** 20-06-2022 **Online:** 16-07-2022

Immunoglobulins

Immunoglobulin or antibodies are the base ground for humoral or antibody mediated immunity. Immunoglobulins are large Y shaped glycoproteins, principally secreted by plasma cells against common pathogens to neutralize them. In all living animals, immunoglobulins are the paramount molecules to fight against infections. The immunoglobulins

are broadly categorized into various types *viz.*, IgM, IgG, IgD, IgE, IgA, IgD2, IgNAR, IgW, IgX, IgY, IgT and HCABs based on structure, type of chain arrangements and molecular weight. The presence of various immunoglobulins in animals are species specific (Vadnais *et al.*, 2017).

Chicken (*Gallus gallus domesticus*) has been utilized in the field of immunology for the purpose or reason out. Hen's immune system differs from mammals in various ways *viz.*, the bursa of fabricius is the most important lymphoid organ present in hens but not in mammals. In chicken the predominant immunoglobulin in serum as well as in egg yolk is IgY, whereas in mammals it is IgG and IgE which are absent in the chicken immune system (Kovacs-Nolan and Mine, 2012).

The B cells in chicken are not major histocompatibility complex restricted lymphocytes and hence can capture soluble antigens. Following invasion of an antigen, the B cells begin clonal expansion and then differentiated into plasma cells which are the main source for antibody production (Taebipour *et al.*, 2017). The chicken immune system has mainly three antibody classes; IgM, IgA and IgY, while the mammal's immune system has five antibody classes namely IgM, IgA, IgG, IgE and IgD (Zhang *et al.*, 2017). Though structural dissimilarities are present between IgY (avian) and IgG (mammals), the functional features are more similar (Kovacs-Nolan and Mine, 2012). IgY antibody shares structural similarities with mammalian IgG, like the antigen-binding fragment (Fab) with complementarity determining regions (CDR) and crystallizable fragments (Fc). However, the IgY antibody lacks a hinge region and has a long heavy chain (Lee *et al.*, 2017). The comparison of IgG and IgY immunoglobulins are given in Table 1.

Chicken IgY production

Chicken IgY name was proposed by Leslie and Clem in 1969 and is different from IgG. IgY is the main low molecular weight immunoglobulin present in serum of chicken and egg yolk. According to the type of antigen, predominant immunocompetent cells and antibody class, the immune response in chicken can be classified as primary or secondary immune response (Gurjar *et al.*, 2013). The primary immune response is characterized by the synthesis of IgM producing cells rather than IgY producing cells with an incipient immune memory. Interestingly, the secondary immune response has higher production of IgY which leads to a solid immune memory than IgG (Meunier *et al.*, 2017; Ou *et al.*, 2017). Transfer of IgY antibodies occurs by their translocation into the egg yolk (Merrill and Grindstaff, 2014; Bernardini *et al.*, 2017). However, the pathogen neutralization ability of IgY in the immunological platform is predominantly influenced by the target antigen. The amount of IgY produced from chicken is influenced by the chicken breed, route, schedule of immunization, extraction and purification methods (Kovacs-Nolan and Mine, 2012).

The concentration of IgY in serum and egg yolk is around 5-20 mg/ml. The molecular mass [kDa] of chicken IgY is about ~ 180 kDa (light chain ~ 25 kDa each; heavy chain ~ 65-68 kDa). The Fc fragment is the most hydrophobic moiety present in IgY molecule (Schade *et al.*, 2005). The production of antigen or fragment specific antibodies using chicken has ultimately gained its importance through high specific antibody retrieval at a low cost (Kovacs-Nolan and Mine, 2012; Diraviyam *et al.*, 2014; Abbas *et al.*, 2019; Pereira *et al.*, 2019). The extinction coefficient (*i.e.* absorbance of a 10 mg/mL solution at 280 nm or optical density of a 1.0 mg/mL solution at 280 nm) for chicken is

Table 1: Comparison of Immunoglobulin G (IgG) and IgY.

Immunoglobulin	IgG	IgY	Reference
Species	Mammals	Birds and reptiles	Pereira <i>et al.</i> , 2019
Source	Serum	Serum/ Egg yolk	Pereira <i>et al.</i> , 2019
Molecular weight (kD)	150	180	Kovacs-Nolan and Mine 2004; Pereira <i>et al.</i> , 2019
Isoelectric point (pI)	1.40	1.36	Li <i>et al.</i> , 2002; Davalos-Pantoja <i>et al.</i> , 2000
No. of constant domains	4	3	Kovacs-Nolan and Mine 2004
Carbohydrate content (%)	2-4	4	Ohta <i>et al.</i> , 1991
Hinge region	Yes	No	Lee <i>et al.</i> , 2017; Pereira <i>et al.</i> , 2019
Antigen valency	2	2	Zhang <i>et al.</i> , 2017
Concentration (mg/ml)	10-12	Serum: 8-10 Yolk: 10-20	Wang <i>et al.</i> , 2000 Carlander, 2002
Percentage of total Ig	80	75	Kovacs-Nolan and Mine, 2004
pH stability	2-11	3.5-11	Pereira <i>et al.</i> , 2019
Stable at >65°C	Yes	No	Kovacs-Nolan and Mine, 2004
Major serum antibody	Yes	Yes	Pereira <i>et al.</i> , 2019
Mammalian complement binding	Yes	No	Kovacs-Nolan and Mine, 2004; Pereira <i>et al.</i> , 2019
Rheumatoid factor binding	Yes	No	Pereira <i>et al.</i> , 2019
Fc receptor binding	Yes	No	Pereira <i>et al.</i> , 2019
Binding to protein A	Yes	No	Pereira <i>et al.</i> , 2019
Binding to protein G	Yes	No	Pereira <i>et al.</i> , 2019
Binding to protein L	Yes	No	Nilsson and Larsson, 2005

1.36 (Leslie and Clem, 1969). The IgY antibodies are mostly limited to antigen-specific (2-10 %) with a productivity of 20-40 grams per year from single chicken (Pauly *et al.*, 2009; Abbas *et al.*, 2019; Pereira *et al.*, 2019). Approximately, 12 eggs contain 1 g of total IgY antibodies, which is equivalent to the total amount of IgG antibodies present in 100 mL of serum. Around 2.5 g of total IgY antibodies can be produced per chicken per month. In chicken targeted antigen-specific proteins or molecules administered through breast muscle of chicken (i.m) with various intervals and passive immunization is about to start from 4 weeks to a year since the last vaccination (Pereira *et al.*, 2019). Unlike in mammal's polyclonal antibody production, the chicken IgY preparation is a non-invasive technique and the amount of immunoglobulin is estimated to be equal to that of 40 rabbits (Kovacs-Nolan and Mine, 2004).

The egg yolk is concentrated daily into the chicken ovarian follicle by the translocation of compounds from blood molecules (Fig 1). Among these compounds, IgY antibodies are most commonly deposited or concentrated in the follicles. The deposition of IgY in egg yolk usually follows a circadian rhythm pattern with five-day intervals between the passage of higher and lower concentrations of IgY (He *et al.*, 2014). The IgY antibodies can be easily extracted from the egg yolk and the process does not require exhaustive procedures like bleeding of the hens.

IgY and its advantages

Passive immunization is generally considered to be only for a short period of effective prevention of infectious diseases similar to maternal colostrum. The existing polyclonal antibodies are generally produced using mice, rats, rabbits, sheep, goats and horses. The principle method of collection

is limited through sera after the target antigen immunization. On a large scale and for industrial purposes, the existing polyclonal antibody production using mammals is less successful due to increased blood necessity in the view of producing significant antibodies for wider application (Kovacs-Nolan and Mine, 2004). In such circumstances, chicken IgY is an effective and alternative method with less animal usage and specific immunoglobulin production (Schade *et al.*, 2005; Diraviyam *et al.*, 2014; Santos *et al.*, 2014; Abbas *et al.*, 2019; Pereira *et al.*, 2019).

In the present era, domestic animals have the capability for producing large scale therapeutics and other biological in infectious disease control. The utility of IgY from the eggs may overcome unnecessary animal usages and invasive techniques (Schade *et al.*, 2005; Diraviyam *et al.*, 2014; Santos *et al.*, 2014; Pereira *et al.*, 2019).

Additionally, IgY does not bind to mammals Fc receptor, rheumatoid factor, or proteins of complement (C1q and C3). Collectively, these features are the most important to prevent the occurrence of false-positive findings in diagnostic research platforms and make IgY a suitable innovation like an immune reagent (Santos *et al.*, 2014; Lee *et al.*, 2017). Thus enhance the need of IgY in various therapeutic areas where an anaphylactic component is unavoidable.

The production of monoclonal antibodies, such as single-chain fragment variable (scFv) by cloning the fragment antigen-binding (Fab) coding genes from the chicken B cell can be achieved easily (Junior *et al.*, 2012; Nie *et al.*, 2014; da Rocha *et al.*, 2017; Borges *et al.*, 2018). Similarly another interesting fact in IgY technology is, it can be used for a long time under various storage conditions without disturbing its functionality such as for a month at 37°C; six months at room temperature and 5-10 years at




Fig 1: IgY antibody translocation from chicken blood to egg yolk in ovarian follicle and IgM, IgA deposition into egg whites through oviduct epithelium.

4°C (Larsson *et al.*, 1993; Nilsson *et al.*, 2012; Abbas *et al.*, 2019). Due to less expensive, more productivity, non-invasive, no cross-reactivity, heat tolerance and pH stability the IgY can be used as a new modality for various clinical purposes (Schade *et al.*, 2005; Kovacs-Nolan and Mine, 2012; Diraviyam *et al.*, 2014; Abbas *et al.*, 2019; Pereira *et al.*, 2019).

IgY applications in human and animal practices

The chicken immunoglobulin (IgY) is widely studied in immunology and medical interventions. The major IgY applications in medical practices are antibacterial, antiviral, antifungal, antiallergic, immune modulator, growth promoter, antivenom, prophylaxis of poisoning, antiobesity, nutritive supplements and diagnostics (Schade *et al.*, 2005; Kovacs-Nolan and Mine, 2012; Diraviyam *et al.*, 2014; Pereira *et al.*, 2019). The detailed information on immunoprophylactic and immunotherapeutic role of IgY in human and animals practice has been furnished with appropriate literature survey for easy understanding.

Immunoprophylactic role of IgY in human and animal diseases

The passive immunization of IgY may produce significant prevention against various infectious diseases and snake poisoning. However, in comparison with active immunization techniques, passive immunization produces a strong and short span of immunity. In a catastrophic pandemic situation, IgY could be used due to the easy and quick production ability with impressive results. The passive prophylactic role of IgY in human and animal species has been studied under various conditions. In humans rotaviral diarrhoea (Rahman *et al.*, 2012), pseudomonas infections (Nilsson *et al.*, 2008), candidiasis (Wilhelmson *et al.*, 2005), dengue (Fink *et al.*, 2017) and streptococcosis (Zhou *et al.*, 2003) were studied. In animals, salmonellosis (Yokoyama *et al.*, 1998; Gurtler *et al.*, 2004), colibacillosis (Ikemori *et al.*, 1992; Yokoyama *et al.*, 1992; Li *et al.*, 2009; Mahdavi *et al.*, 2010; Germine *et al.*, 2011), rotaviral diarrhea (Vega *et al.*, 2011), infectious bursal disease (Yousif *et al.*, 2006), porcine epidemic diarrhea (Kweon *et al.*, 2000), coccidiosis (Lee *et al.*, 2009a,b), clostridial infections (Pizarro-Guajardo *et al.*, 2017), vibriosis (Hirai *et al.*, 2010), staphylococcosis (Leclaire *et al.*, 2002), streptococcosis (Zhou *et al.*, 2003), white spot syndrome (Lu *et al.*, 2009), flu (Tsukamoto *et al.*, 2011), hantaviral pneumonia (Haese *et al.*, 2015), tetanus (Selim *et al.*, 2015), snake poisoning (Paul *et al.*, 2007; Meenatchisundaram *et al.*, 2008a,b; de Almeida *et al.*, 2008; Lee *et al.*, 2016), rabies (Motoi *et al.*, 2005) and phytate phosphate toxicity (Bobeck *et al.*, 2016) were studied.

Immunotherapeutic role of IgY in human and animal diseases

The IgY derived against specific pathogen may be helpful in the treatment of various infectious diseases with high neutralization ability resulting in increased recovery rate and reduced host damage through elimination of microbial load. The short lifespan of IgY in mammalian host (maximum 36

hours) results in increased clearance leading to easy elimination of infectious agents (da Silva and Tambourgi, 2010). Immunotherapeutic role of IgY were studied extensively in humans against common infectious diseases like rotaviral diseases (Sarker *et al.*, 2001; Rahman *et al.*, 2012) and streptococcosis (Zhou *et al.*, 2003). Similarly in animals, IgY has been used as immunotherapeutic in various fungal, bacterial, parasitic and viral diseases *viz.*, colibacillosis (Cook *et al.*, 2005; Germine *et al.*, 2011), salmonellosis (Gurtler *et al.*, 2004), canine parvoviral enteritis (Van Nguyen *et al.*, 2006; Suartini *et al.*, 2014; Naveenkumar *et al.*, 2019) and trypanosomiasis (Sampaio *et al.*, 2014). Moreover, it has also been used in treatment of snake bite cases (Paul *et al.*, 2007; Meenatchisundaram *et al.*, 2008a,b; de Almeida *et al.*, 2008; Lee *et al.*, 2016).

Immunodiagnostic role of IgY in human and animal diseases

As of now, mammalian infectious diseases are diagnosed with antigen and or antibody detection. In large scale surveillance and other practices, antibody detection with a primary binding assay such as enzymatic linked immunosorbent assay (ELISA), lateral fluorescent assays, immune chromatography, etc are adopted. The major drawback of current diagnostic method is cross-reactivity with other similar pathogens which reduce the specificity (Parida *et al.*, 2008; Magtoto *et al.*, 2019). In those areas, IgY based ELISA will be an outstanding diagnostic kit as it avoid false-positive results. Due to IgY specific targeted pathogen in ELISA, cross-reactivity with other similar pathogens would not happen (Reddy *et al.*, 2013; Shapouri *et al.*, 2018; Constantin *et al.*, 2020). Additionally, IgY technique will be used for immunodiagnostics such as antigen-binding repertoire, which is achieved by gene conversion using the insertion of segments from pseudogenes (Kaiser, 2012); avidity maturation; enzyme and fluorescence antibody conjugation and immune-gold beads antibody labeling (Shapouri *et al.*, 2018; Constantin *et al.*, 2020).

Role of IgY in biowar

Immunoglobulin Y has a significant application in the protection against bioterrorism microbes *viz.*, *Staphylococcus* enterotoxin B (Leclaire *et al.*, 2002). In biowar situations, the production of vaccines is a much challenging task for large scale population. In such circumstances, passive immunization against the bio-warfare agents will be much beneficial for large population, though the prevention is not for a long phase (Pereira *et al.*, 2019). Microbial resistance can also be counteracted by the use of IgY technology (Diraviyam *et al.*, 2014). Dissemination of field level therapeutic as well as passive prevention methods is much affordable by using IgY.

Role of IgY in food preservation and other scopes

In food industry chemical preservatives are commonly used to avoid microbial spoilage. Biological preservatives are

required by the industries for better stability. In such circumstances IgY has been found to be very good as natural preservative. Due to the specificity in neutralization of spoilage organisms and merit of quick clearance in mammals gastrointestinal tract, IgY is preferred in food industries (Baloch *et al.*, 2015; Zorriehzahra *et al.*, 2016). The use of earlier IgY against common spoilage organisms *viz.*, *Listeria monocytogenes*, *Shewanella putrefaciens* and *Pseudomonas fluorescens* (Sui *et al.*, 2011; Xu *et al.*, 2012; Zhang *et al.*, 2015) has been reported.

Additionally, IgY utility were reported in various modes such as anti-obesity (Hirose *et al.*, 2013; Tarigan *et al.*, 2016), anti-allergy with immunomodulatory effects (Wei-Xu *et al.*, 2016) and as growth promoter (Cook, 2002; 2004). Potential zoonotic agent vaccines can also be developed which will reduce the chances of zoonosis. *Brucella* vaccine strain with IgY has been studied *in-vitro* with good success rate (Moreno *et al.*, 2016). Zoonotic pathogen intervention tools with reducing health professional risk are much warranted theme in the current scenario (Moreno *et al.*, 2016; Hans *et al.*, 2020).

The current scenario with the pandemic load of COVID-19, possess the need for suitable antiviral vaccine for devising control strategies. The challenging attributes of COVID-19 virus have resulted in the delay in the production of vaccines and other suitable medical counter measures (Wu *et al.*, 2020). In such circumstances, IgY is a wonderful research area in which the production time will be minimal compared with vaccine production (Constantin *et al.*, 2020). The role of antigen site determination is a challenging task for the current pandemic (Wu *et al.*, 2020). Interestingly the role of IgY in SARS-CoV was studied in *in-vitro* set up and found to be more effective in the prevention and control of the viral load (Fu *et al.*, 2006). Though the similarities between SARS-CoV and COVID-19 (SARS-CoV-2) were well documented in terms of phylogenicity and respiratory system effect, still it needs to be studied effectively both *in-vitro* and *in vivo* for IgY based therapeutic approach (Wu *et al.*, 2020). In emerging, re-emerging infections and other unpredictable situations IgY could be a suitable candidate to control the spectrum of the epidemic in a short period (Constantin *et al.*, 2020).

CONCLUSION/ FUTURE PERSPECTIVES

Active immunization through a potent vaccine strain is very important to control epidemics of infectious diseases. Due to pathogen mutation, the epidemics are unpredictable resulting in delays in finding active immunization. In those circumstances, passive immunization with chicken antibodies (IgY) is a recent techniques with various positive factors *viz.*, low cost, non-invasive, reduced animal numbers, non-allergic, non-cross-reactive and increased production. In the present scenario in finding alternate way for antimicrobials, IgY is one of the promising techniques in therapeutics. Additionally, antimicrobial resistance issues will be manageable while using IgY. The specificity of IgY is a fully dependable factor on targeted antigen used for

vaccination. In a nutshell, IgY is a sound technique in the immunology of human and animal clinical practice and the role of IgY in all areas of clinical practice must be studied in future.

ACKNOWLEDGEMENT

All the authors acknowledge and thank their respective Institutes and Universities.

Conflict of interest

The authors report no conflict of interest.

REFERENCES

- Abbas, A.T., El-Kafrawy, S.A., Sohrab, S.S., Azhar, E.I.A. (2019). IgY antibodies for the immunoprophylaxis and therapy of respiratory infections. *Human Vaccines and Immunotherapeutics*. 15: 264-275.
- Asokan, G. and Kasimanickam, R. (2013). Emerging infectious diseases, antimicrobial resistance and millennium development goals: resolving the challenges through one health. *Central Asian Journal of Global Health*. 2: 76.
- Baloch, A.R., Zhang, X.Y., Schade, R. (2015). IgY Technology in aquaculture-A review. *Reviews in Aquaculture*. 7: 153-160.
- Bernardini, R., Aufieri, R., Detcheva, A., Recchia, S., Cicconi, R., Amicosante, M., Montesano, C., Rossi, P., Tchidjou, H.K., Petrunov, B. (2017). Neonatal protection and preterm birth reduction following maternal group B streptococcus vaccination in a mouse model. *The Journal of Maternal-Fetal and Neonatal Medicine*. 30: 2844-2850.
- Bobeck, E.A., Hellestad, E.M., Helvig, C.F., Petkovich, P.M., Cook, M.E. (2016). Oral antibodies to human intestinal alkaline phosphatase reduce dietary phytate phosphate bioavailability in the presence of dietary 1 α -hydroxycholecalciferol. *Poultry Science*. 95: 570-580.
- Borges, I.P., Silva, M.F., Santiago, F.M., De Faria, L.S., Júnior, Á.F., Da Silva, R.J., Costa, M.S., De Freitas, V., Yoneyama, K.A.G., Ferro, E.A.V. (2018). Antiparasitic effects induced by polyclonal IgY antibodies anti-phospholipase A2 from *Bothropspauloensis* venom. *International Journal of Biological Macromolecules*. 112: 333-342.
- Carlander, D. (2002). Avian IgY Antibody - in vitro and in vivo (Ph.D. thesis in Faculty of Medicine). Sweden, Uppsala: Acta Universitatis Upsaliensis.
- Constantin, C., Neagu, M., Supeanu, T.D., Chiurciu, V., Spandidos, D.A. (2020). IgY turning the page toward passive immunization in COVID-19 infection. *Experimental and Therapeutic Medicine*. 20: 151-158.
- Cook, M.E. (2002). Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency. Wisconsin Alumni Research Foundation (US Patent 6383485).
- Cook, M. (2004). Antibodies: Alternatives to antibiotics in improving growth and feed efficiency. *Journal of Applied Poultry Research*. 13: 106-119.
- Cook, S., Bach, S., Stevenson, S., Deviney, R., Frohlich, A., Fang, L., Mcallister, T. (2005). Orally administered anti-*Escherichia coli* O157: H7 chicken egg yolk antibodies reduce fecal shedding of the pathogen by ruminants. *Canadian Journal of Animal Science*. 85: 291-299.

- Cromwell, G.L. (2002). Why and how antibiotics are used in swine production. *Animal Biotechnology*. 13: 7-27.
- Da Rocha, D.G., Fernandez, J.H., De Almeida, C.M.C., Da Silva, C.L., Magnoli, F.C., Da Silva, O.É., Da Silva, W.D. (2017). The complementarity-determining region sequences in IgY antivenom hypervariable regions. *Data in Brief*. 13: 717-722.
- Da Silva, W.D., Tambourgi, D.V. (2010). IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. *Veterinary Immunology and Immunopathology*. 135: 173-180.
- Davalos-Pantoja, L., Ortega-Vinuesa, J., Bastos-Gonzalez, D., Hidalgo-Alvarez, R. (2000). A comparative study between the adsorption of IgY and IgG on latex particles. *Journal of Biomaterials Science, Polymer Edition*. 11: 657-673.
- De Almeida, C.M.C., Da Silva, C.L., Couto, H.P., Escocard, R.D.C.M., Da Rocha, D.G., De Paula Sentinelli, L., Kipnis, T.L., Da Silva, W.D. (2008). Development of process to produce polyvalent IgY antibodies anti-African snake venom. *Toxicon*. 52: 293-301.
- Diraviyam, T., Zhao, B., Wang, Y., Schade, R., Michael, A., Zhang, X. (2014). Effect of chicken egg yolk antibodies (IgY) against diarrhea in domesticated animals: A systematic review and meta-analysis. *PLoS one*. 9: e97716.
- Fink, A.L., Williams, K.L., Harris, E., Alvine, T.D., Henderson, T., Schiltz, J., Nilles, M.L., Bradley, D.S. (2017). Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement. *PLoS Neglected Tropical Diseases*. 11: e0005721.
- Fu, C.Y., Huang, H., Wang, X.M., Liu, Y.G., Wang, Z.G., Cui, S.J., Gao, H.L., Li, Z., Li, J.P., Kong, X.G. (2006). Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens. *Journal of Virological Methods*. 133: 112-115.
- Germine, S., Ebied, M., Ibrahim, F., Mettias, K., Daoud, A. (2011). Field evaluation of egg yolk antibodies in prevention and treatment of Enteric colibacillosis in calves. *Benha Veterinary Medical Journal*. SI-I:108-114.
- Gurjar, R.S., Gulley, S.L., VanGinkel, F.W. (2013). Cell-mediated immune responses in the head-associated lymphoid tissues induced to a live attenuated avian coronavirus vaccine. *Developmental and Comparative Immunology*. 41: 715-722.
- Gürtler, M., Methner, U., Kobilke, H., Fehhaber, K. (2004). Effect of orally administered egg yolk antibodies on Salmonella enteritidis contamination of hen's eggs. *Journal of Veterinary Medicine. Series B*, 51: 129-134.
- Haese, N., Brocato, R.L., Henderson, T., Nilles, M.L., Kwilas, S.A., Josleyn, M.D., Hammerbeck, C.D., Schiltz, J., Royals, M., Ballantyne, J. (2015). Antiviral biologic produced in DNA vaccine/goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. *PLoS Neglected Tropical Diseases*. 9: e0003803.
- Hans, R., Yadav, P.K., Sharma, P.K., Boopathi, M., Thavaselvam, D. (2020). Development and validation of immunoassay for whole cell detection of *Brucella abortus* and *Brucella melitensis*. *Scientific reports*. 10: 1-13.
- He, J.X., Thirumalai, D., Schade, R., Zhang, X.Y. (2014). Chronobiological studies of chicken IgY: Monitoring of infradian, circadian and ultradian rhythms of IgY in blood and yolk of chickens. *Veterinary Immunology and Immunopathology*. 160: 266-272.
- Hirai, K., Arimitsu, H., Umeda, K., Yokota, K., Shen, L., Ayada, K., Kodama, Y., Tsuji, T., Hirai, Y., Oguma, K. (2010). Passive oral immunization by egg yolk immunoglobulin (IgY) to *Vibrio cholerae* effectively prevents cholera. *Acta Medica Okayama*. 64: 163-170.
- Hirose, M., Ando, T., Shofiqur, R., Umeda, K., Kodama, Y., Van Nguyen, S., Goto, T., Shimada, M., Nagaoka, S. (2013). Anti-obesity activity of hen egg anti-lipase immunoglobulin yolk, a novel pancreatic lipase inhibitor. *Nutrition and Metabolism*. 10: 1-6.
- Ikemori, Y., Kuroki, M., Peralta, R.C., Yokoyama, H., Kodama, Y. (1992). Protection of neonatal calves against fatal enteric colibacillosis by administration of egg yolk powder from hens immunized with K99-piliated enterotoxigenic *Escherichia coli*. *American Journal of Veterinary Research*. 53: 2005-2008.
- Junior, A.F., Santiago, F.M., Silva, M.V., Ferreira, F.B., Junior, A.G., Mota, C.M., Faria, M.S., Silva Filho, H.H., Silva, D.A., Cunha-Junior, J.P., Mineo, J.R. (2012). Production, characterization and applications for *Toxoplasma gondii*-specific polyclonal chicken egg yolk immunoglobulins. *PLoS One*. 7: e40391.
- Kaiser, P. (2012). The long view: A bright past, a brighter future? Forty years of chicken immunology pre-and post-genome. *Avian Pathology*. 41: 511-518.
- Kovacs-Nolan, J and Mine, Y. (2004). Avian egg antibodies: Basic and potential applications. *Avian and Poultry Biology Reviews*. 15: 25-46.
- Kovacs-Nolan, J and Mine, Y. (2012). Egg yolk antibodies for passive immunity. *Annual Review of Food Science and Technology*. 3: 163-182.
- Kweon, C.H., Kwon, B.J., Woo, S.R., Kim, J.M., Woo, G.H., Son, D.H., Hur, W., Lee, Y.S. (2000). Immunoprophylactic effect of chicken egg yolk immunoglobulin (Ig Y) against porcine epidemic diarrhea virus (PEDV) in piglets. *Journal of Veterinary Medical Science*. 62: 961-964.
- Larsson, A., Bålöv, R.M., Lindahl, T.L., Forsberg, P.O. (1993). Chicken antibodies: taking advantage of evolution-A review. *Poultry science*. 72: 1807-1812.
- Leclaire, R.D., Hunt, R.E., Bavari, S. (2002). Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. *Infection and Immunity*. 70: 2278-2281.
- Lee, C.H., Lee, Y.C., Leu, S.J., Lin, L.T., Chiang, J.R., Hsu, W.J., Yang, Y.Y. (2016). Production and characterization of neutralizing antibodies against *Bungarus multicinctus* snake venom. *Applied and Environmental Microbiology*. 82: 6973-6982.
- Lee, S., Lillehoj, H., Park, D., Jang, S., Morales, A., Garcia, D., Lucio, E., Larios, R., Victoria, G., Marrufo, D. (2009b). Protective effect of hyperimmune egg yolk IgY antibodies against *Eimeria tenella* and *Eimeria maxima* infections. *Veterinary Parasitology*. 163: 123-126.

- Lee, S.H, Lillehoj, H., Park, D., Jang, S., Morales, A., García, D., Lucio, E., Larios, R., Victoria, G., Marrufo, D. (2009a). Induction of passive immunity in broiler chickens against *Eimeria acervulina* by hyperimmune egg yolk immunoglobulin Y. *Poultry Science*. 88: 562-566.
- Lee, W., Atif, A.S., Tan, S.C., Leow, C.H. (2017). Insights into the chicken IgY with emphasis on the generation and applications of chicken recombinant monoclonal antibodies. *Journal of Immunological Methods*. 447: 71-85.
- Leslie, G.A and Clem, L.W. (1969). Phylogeny of immunoglobulin structure and function: III. Immunoglobulins of the chicken. *The Journal of Experimental Medicine*. 130: 1337-1352.
- Li, G., Stewart, R., Conlan, B., Gilbert, A., Roeth, P., Nair, H. (2002). Purification of human immunoglobulin G: a new approach to plasma fractionation. *Vox sanguinis*. 83: 332-338.
- Li, X.Y., Jin, L.J., Uzonna, J.E., Li, S.Y., Liu, J.J., Li, H.Q., Lu, Y.N., Zhen, Y.H., Xu, Y.P. (2009). Chitosan-alginate microcapsules for oral delivery of egg yolk immunoglobulin (IgY): In vivo evaluation in a pig model of enteric colibacillosis. *Veterinary Immunology and Immunopathology*. 129: 132-136.
- Lu, Y., Liu, J., Jin, L., Li, X., Zhen, Y., Xue, H., Lin, Q., Xu, Y. (2009). Passive immunization of crayfish (*Procambarus clarkia*) with chicken egg yolk immunoglobulin (IgY) against white spot syndrome virus (WSSV). *Applied Biochemistry and Biotechnology*. 159: 750-758.
- Magtoto, R., Poonsuk, K., Baum, D., Zhang, J., Chen, Q., Ji, J., Piñeyro, P., Zimmerman, J., Giménez-Lirola, L.G. (2019). Evaluation of the serologic cross-reactivity between transmissible gastroenteritis coronavirus and porcine respiratory coronavirus using commercial blocking enzyme-linked immunosorbent assay kits. *Mosphere*. 4: e00017-19.
- Mahdavi, A.H., Rahmani, H., Nili, N., Samie, A., Soleimani-Zad, S., Jahanian, R. (2010). Effects of dietary egg yolk antibody powder on growth performance, intestinal *Escherichia coli* colonization and immunocompetence of challenged broiler chicks. *Poultry Science*. 89: 484-494.
- Meenatchisundaram, S., Parameswari, G., Michael, A., Ramalingam, S. (2008a). Neutralization of the pharmacological effects of Cobra and Krait venoms by chicken egg yolk antibodies. *Toxicon*. 52: 221-227.
- Meenatchisundaram, S., Parameswari, G., Michael, A., Ramalingam, S. (2008b). Studies on pharmacological effects of Russell's viper and Saw-scaled viper venom and its neutralization by chicken egg yolk antibodies. *International Immuno pharmacology*. 8: 1067-1073.
- Merrill, L and Grindstaff, J.L. (2014). Maternal antibody transfer can lead to suppression of humoral immunity in developing zebra finches (*Taeniopygia guttata*). *Physiological and Biochemical Zoology*. 87: 740-751.
- Meunier, M., Guyard-Nicodème, M., Vigouroux, E., Poezevara, T., Beven, V., Quesne, S., Bigault, L., Amelot, M., Dory, D., Chemaly, M. (2017). Promising new vaccine candidates against *Campylobacter* in broilers. *PLoS one*. 12: e0188472.
- Moreno, C., Zerpa, N., Malavé, C., Bermúdez, H., Demey, J., Fernandez-Gomez, R., Ilzins, O. (2016). Development and characterization of IgY antibodies against synthetic peptides from *Brucella abortus* OMP25 and BP26 proteins. *Boletín de Malariología y Salud Ambiental*. 56: 192-201.
- Motoi, Y., Sato, K., Hatta, H., Morimoto, K., Inoue, S., Yamada, A. (2005). Production of rabies neutralizing antibody in hen's eggs using a part of the G protein expressed in *Escherichia coli*. *Vaccine*. 23: 3026-3032.
- Naveenkumar, V., Bharathi, M.V., Nagarajan, B. (2019). Heterogenous immunoglobulin Y (IgY) therapy: A new modality in canine parvovirus enteritis treatment. *Indian Veterinary Journal*. 96: 76-77.
- Nie, G., Wang, T., Lu, S., Liu, W., Li, Y., Lei, J. (2014). Detection of *Clonorchis sinensis* circulating antigen in sera from Chinese patients by immunomagnetic bead ELISA based on IgY. *PLoS One*. 9: e113208.
- Nilsson, E., Larsson, A., Olesen, H.V., Wejåker, P.E., Kollberg, H. (2008). Good effect of IgY against *Pseudomonas aeruginosa* infections in cystic fibrosis patients. *Pediatric Pulmonology*. 43: 892-899.
- Nilsson, E and Larsson, A. (2005). Chicken anti-protein L for the detection of small amounts of protein L in the presence of IgG. *Hybridoma*. 24: 112-114.
- Nilsson, E., Stålborg, J., Larsson, A. (2012). IgY stability in eggs stored at room temperature or at + 4°C. *British Poultry Science*. 53: 42-46.
- Ohta, M., Hamako, J., Yamamoto, S., Hatta, H., Kim, M., Yamamoto, T., Oka, S., Mizuochi, T., Matsuura, F. (1991). Structures of asparagine-linked oligosaccharides from hen egg-yolk antibody (IgY). Occurrence of unusual glucosylated oligomannose type oligosaccharides in a mature glycoprotein. *Glycoconjugate Journal*. 8: 400-413.
- Ou, H., Yao, W., Yu, D., Weng, T., Wang, F.X., Wu, X., Wu, H., Cheng, L., Lu, X., Wu, N. (2017). Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice. *Oncotarget*. 8: 91828.
- Parida, M., Sannarangaiah, S., Dash, P.K., Rao, P., Morita, K. (2008). Loop mediated isothermal amplification (LAMP): A new generation of innovative gene amplification technique; perspectives in clinical diagnosis of infectious diseases. *Reviews in Medical Virology*. 18: 407-421.
- Paul, K., Manjula, J., Deepa, E., Selvanayagam, Z., Ganesh, K., Rao, P.S. (2007). Anti-Echiscarinatus venom antibodies from chicken egg yolk: Isolation, purification and neutralization efficacy. *Toxicon*. 50: 893-900.
- Pauly, D., Dorner, M., Zhang, X., Hlinak, A., Dorner, B., Schade, R. (2009). Monitoring of laying capacity, immunoglobulin Y concentration and antibody titer development in chickens immunized with ricin and botulinum toxins over a two-year period. *Poultry Science*. 88: 281-290.
- Pereira, E., Van Tilburg, M., Florean, E., Guedes, M. (2019). Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. *International Immuno pharmacology*. 73: 293-303.
- Pizarro-Guajardo, M., Díaz-González, F., Álvarez-Lobos, M., Paredes-Sabja, D. (2017). Characterization of chicken IgY specific to *Clostridium difficile* R20291 spores and the effect of oral administration in mouse models of initiation and recurrent disease. *Frontiers in Cellular and Infection Microbiology*. 7: 365.

- Rahman, S., Higo-Moriguchi, K., Htun, K.W., Taniguchi, K., Icatlo, J.F.C., Tsuji, T., Kodama, Y., Van Nguyen, S., Umeda, K., Oo, H.N. (2012). Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. *Vaccine*. 30: 4661-4669.
- Reddy, P.K., Shekar, A., Kingston, J.J., Sripathy, M.H., Batra, H. (2013). Evaluation of IgY capture ELISA for sensitive detection of Alpha hemolysin of *Staphylococcus aureus* without staphylococcal protein A interference. *Journal of Immunological Methods*. 391: 31-38.
- Sampaio, L.C., Baldissera, M.D., Grando, T.H., Gressler, L.T., de Menezes Capeleto, D., de Sa, M.F., de Jesus, F.P., dos Santos Junior, A.G., Anciuti, A.N., Colanetti, K., Stainki, D.R. (2014). Production, purification and therapeutic potential of egg yolk antibodies for treating *Trypanosoma evansi* infection. *Veterinary Parasitology*. 204: 96-103.
- Santos, F.N., Brum, B.C., Cruz, P.B., Molinaro, C.M., Silva, V.L., Chaves, S.A.D.M. (2014). Production and characterization of IgY against canine IgG: prospect of a new tool for the immunodiagnostic of canine diseases. *Brazilian Archives of Biology and Technology*. 57: 523-531.
- Sarker, S.A., Casswall, T.H., Juneja, L.R., Hoq, E., Hossain, I., Fuchs, G.J., Hammarström, L. (2001). Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. *Journal of Pediatric Gastroenterology and Nutrition*. 32: 19-25.
- Schade, R., Calzado, E.G., Sarmiento, R., Chacana, P.A., Porankiewicz-Asplund, J., Terzolo, H.R. (2005). Chicken egg yolk antibodies (IgY-technology): A review of progress in production and use in research and human and veterinary medicine. *Alternatives to Laboratory Animals*. 33: 129-154.
- Selim, A., Ibrahim, E., El, M.A., Hamouda, F. (2015). Development of IgY antibodies for control of tetanus. *Biotechnology in Animal Husbandry*. 31: 109-122.
- Shapouri, M.R.S.A., Rashno, M., Mahmoodi, P., Aria, M. (2018). Production of a monoclonal antibody against chicken immunoglobulin G: A valuable molecule with research and diagnostic applications. *Veterinary Research Forum*. 9: 61-72.
- Suartini, G.A., Suprayogi, A., Wibawan, W.T., Sendow, I., Mahardika, G.N. (2014). Intravenous administration of chicken immunoglobulin has a curative effect in experimental infection of canine parvovirus. *Global Veterinaria*. 13: 801-808.
- Sui, J., Cao, L., Lin, H. (2011). Antibacterial activity of egg yolk antibody (IgY) against *Listeria monocytogenes* and preliminary evaluation of its potential for food preservation. *Journal of the Science of Food and Agriculture*. 91: 1946-1950.
- Taebipour, M.J., Dadras, H., Nazifi, S., Afsar, M., Ansari-Lari, M. (2017). Evaluation of blood monocyte and lymphocyte population in broiler chicken after vaccination and experimental challenge with Newcastle disease virus. *Veterinary Immunology and Immunopathology*. 190: 31-38.
- Tarigan, R., Kusumorini, N., Manalu, W. (2016). Effectivity of Immunoglobulin Y Anti Lipase as a Pancreatic Lipase Inhibitor for Prevention of Obesity. *Pakistan Journal of Nutrition*. 15: 625-632.
- Tsukamoto, M., Hiroi, S., Adachi, K., Kato, H., Inai, M., Konishi, I., Tanaka, M., Yamamoto, R., Sawa, M., Handharyani, E. (2011). Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1. *Molecular Medicine Reports*. 4: 209-214.
- Turner, J., Dritz, S., Minton, J. (2001). Alternatives to conventional antimicrobials in swine diets. *The Professional Animal Scientist*. 17: 217-226.
- Vadnais, M.L., Criscitiello, M.F., Smider, V.V. (2017). Antibodies from Other Species. *Protein Therapeutics*. 1: 85-112.
- Van Nguyen, S., Umeda, K., Yokoyama, H., Tohya, Y., Kodama, Y. (2006). Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk. *Canadian Journal of Veterinary Research*. 70: 62.
- Vega, C., Bok, M., Chacana, P., Saif, L., Fernandez, F., Parreño, V. (2011). Egg yolk IgY: protection against rotavirus induced diarrhea and modulatory effect on the systemic and mucosal antibody responses in newborn calves. *Veterinary Immunology and Immunopathology*. 142: 156-169.
- Ventola, C.L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and Therapeutics*. 40: 277.
- Wang, Y., Cherian, G., Sunwoo, H., Sim, J. (2000). Dietary polyunsaturated fatty acids significantly affect laying hen lymphocyte proliferation and immunoglobulin G concentration in serum and egg yolk. *Canadian Journal of Animal Science*. 80: 597-604.
- Wei-Xu, H., Wen-Yun, Z., Xi-Ling, Z., Zhu, W., Li-Hua, W., Xiao-Mu, W., Hui-Ping, W., Wen-Ding, W., Dan, H., Qin, X. (2016). Anti-Interleukin-1 beta/tumor necrosis factor-alpha IgY antibodies reduce pathological allergic responses in guinea pigs with allergic rhinitis. *Mediators of Inflammation*, 2016. DOI: 10.1155/2016/3128182.
- Wilhelmson, M., Carlander, D., Kreuger, A., Kollberg, H., Larsson, A. (2005). Oral treatment with yolk antibodies for the prevention of *C. albicans* infections in chemotherapy treated children. A feasibility study. *Food and Agricultural Immunology*. 16: 41-45.
- Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*. 10: 766-788. DOI: 10.1016/j.apsb.2020.02.008.
- Xu, Y., Lin, H., Sui, J., Cao, L. (2012). Effects of specific egg yolk antibody (IgY) on the quality and shelf life of refrigerated *Paralichthys solivaceus*. *Journal of the Science of Food and Agriculture*. 92: 1267-1272.
- Yokoyama, H., Peralta, R.C., Diaz, R., Sendo, S., Ikemori, Y., Kodama, Y. (1992). Passive protective effect of chicken egg yolk immunoglobulins against experimental enterotoxigenic *Escherichia coli* infection in neonatal piglets. *Infection and Immunity*. 60: 998-1007.
- Yokoyama, H., Peralta, R.C., Umeda, K., Hashi, T., Icatlo Jr, F., Kuroki, M., Ikemori, Y., Kodama, Y. (1998). Prevention of fatal salmonellosis in neonatal calves, using orally administered chicken egg yolk *Salmonella*-specific antibodies. *American Journal of Veterinary Research*. 59: 416-420.

- Yousif, A.A., Mohammad, W.A., Khodeir, M.H., Zeid, A., El-Sanousi, A.A., Saber, M.S., Reda, I.M. (2006). Oral administration of hyperimmune IgY: An immunoeological approach to curbing acute infectious bursal disease virus infection. *Egypt Journal of Immunology*. 13: 85-94.
- Zhang, Q., Lin, H., Sui, J., Wang, J., Cao, L. (2015). Effects of Fab2 fragments of specific egg yolk antibody (IgY Fab2) against *Shewanella putrefaciens* on the preservation of refrigerated turbot. *Journal of the Science of Food and Agriculture*. 95: 136-140.
- Zhang, X., Calvert, R.A., Sutton, B.J., Doré, K.A. (2017). IgY: A key isotype in antibody evolution. *Biological Reviews*. 92: 2144-2156.
- Zhou, Z., Zhou, R., Tang, Z. (2003). Effects of topical application of immunoglobulin yolk on mutans streptococci in dental plaque. *Hua xi kouqianguyixue za zhi= Huaxikouqiang yixuezazhi= West China journal of stomatology*. 21: 295-297.
- Zorriehzahra, M.J., Tiwari, R., Sachan, S., Karthik, K., Malik, Y.S., Dadar, M., Sarwar, M., Sayab, M., Dhama, K. (2016). Avian Egg Yolk Antibodies (IgY) and their Potential Therapeutic Applications for Countering Infectious Diseases of Fish and Aquatic Animals. *International Journal of Pharmacology*. 12: 760-768.